| 1 |
34560683 |
10.1097/PAS.0000000000001813 |
2022 |
A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients. |
B2M |
| 2 |
34614146 |
10.1182/blood.2020010263 |
2022 |
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. |
B2M |
| 3 |
34664256 |
10.1111/bjh.17894 |
2022 |
Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA. |
B2M |
| 4 |
35075971 |
10.1080/10428194.2021.2010060 |
2022 |
Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study. |
B2M |
| 5 |
35368100 |
10.1002/hon.2994 |
2022 |
A novel clinical immune-related prognostic model predicts the overall survival of mantle cell lymphoma. |
B2M |
| 6 |
35611992 |
10.1002/gcc.23069 |
2022 |
Primary mediastinal large B-cell lymphoma is characterized by large-scale copy-neutral loss of heterozygosity. |
B2M |
| 7 |
35795062 |
10.3389/fonc.2022.870487 |
2022 |
Plasma Concentrations and Cancer-Associated Mutations in Cell-Free Circulating DNA of Treatment-Naive Follicular Lymphoma for Improved Non-Invasive Diagnosis and Prognosis. |
B2M |
| 8 |
35885481 |
10.3390/diagnostics12071575 |
2022 |
Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma. |
B2M |
| 9 |
36001451 |
10.1097/PAS.0000000000001956 |
2022 |
Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas. |
B2M |
| 10 |
36055572 |
10.1016/j.clim.2022.109105 |
2022 |
A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma. |
B2M |
| 11 |
32079702 |
10.3324/haematol.2019.237719 |
2021 |
Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study. |
B2M |
| 12 |
32961552 |
10.1182/blood.2020007507 |
2021 |
Mutational landscape of gray zone lymphoma. |
B2M |
| 13 |
32964767 |
10.1080/10428194.2020.1821011 |
2021 |
Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas. |
B2M |
| 14 |
33311649 |
10.1038/s41379-020-00720-7 |
2021 |
Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice. |
B2M |
| 15 |
33332932 |
10.4143/crt.2020.1060 |
2021 |
Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels. |
B2M |
| 16 |
33567641 |
10.3390/cancers13040682 |
2021 |
Genomic Landscape of Hodgkin Lymphoma. |
B2M |
| 17 |
33569430 |
10.21037/atm-20-7574 |
2021 |
Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity. |
B2M |
| 18 |
33747936 |
10.3389/fonc.2021.622648 |
2021 |
Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. |
B2M |
| 19 |
33777778 |
10.3389/fonc.2021.628807 |
2021 |
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. |
B2M |
| 20 |
33964277 |
10.1016/j.humpath.2021.04.014 |
2021 |
Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma. |
B2M |
| 21 |
34050029 |
10.1073/pnas.2104504118 |
2021 |
Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. |
B2M |
| 22 |
34050261 |
10.1038/s41375-021-01284-4 |
2021 |
Lymphoma and multiple myeloma in cohorts of persons exposed to ionising radiation at a young age. |
B2M |
| 23 |
34312841 |
10.1111/bjh.17719 |
2021 |
Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping. |
B2M |
| 24 |
34374220 |
10.1002/cjp2.223 |
2021 |
c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma. |
B2M |
| 25 |
34478526 |
10.1182/bloodadvances.2021005215 |
2021 |
Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. |
B2M |
| 26 |
35008340 |
10.3390/cancers14010176 |
2021 |
Recent Advances in the Genetic of MALT Lymphomas. |
B2M |
| 27 |
31242129 |
10.1080/15548627.2019.1635380 |
2020 |
<i>MIR145-3p</i> promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting <i>HDAC4</i>. |
B2M |
| 28 |
31782146 |
10.1111/bjh.16263 |
2020 |
New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). |
B2M |
| 29 |
31804029 |
10.1111/ejh.13364 |
2020 |
Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. |
B2M |
| 30 |
31822802 |
10.1038/s41379-019-0428-0 |
2020 |
Diagnostic utility of STAT6<sup>YE361</sup> expression in classical Hodgkin lymphoma and related entities. |
B2M |
| 31 |
32172489 |
10.1007/s10637-020-00916-3 |
2020 |
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. |
B2M |
| 32 |
32304999 |
10.1016/j.ebiom.2020.102731 |
2020 |
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. |
B2M |
| 33 |
32399964 |
10.1002/ijc.33049 |
2020 |
Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup. |
B2M |
| 34 |
32565964 |
10.3892/ol.2020.11552 |
2020 |
Comprehensive characterization of driver genes in diffuse large B cell lymphoma. |
B2M |
| 35 |
33252851 |
10.1002/ctm2.221 |
2020 |
Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma. |
B2M |
| 36 |
30108156 |
10.1634/theoncologist.2018-0058 |
2019 |
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. |
B2M |
| 37 |
30591526 |
10.1182/blood-2018-08-862292 |
2019 |
Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints. |
B2M |
| 38 |
30792096 |
10.1016/j.clml.2019.01.003 |
2019 |
Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study. |
B2M |
| 39 |
30942640 |
10.1080/10428194.2019.1594212 |
2019 |
Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma. |
B2M |
| 40 |
31006875 |
10.1002/ajh.25493 |
2019 |
Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. |
B2M |
| 41 |
31205619 |
10.1016/j.csbj.2019.03.006 |
2019 |
Application of PD-1 Blockade in Cancer Immunotherapy. |
B2M |
| 42 |
31211907 |
10.1111/ejh.13274 |
2019 |
The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma. |
B2M |
| 43 |
31292115 |
10.1182/blood.2019001126 |
2019 |
Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. |
B2M |
| 44 |
31324639 |
10.1182/bloodadvances.2018026591 |
2019 |
IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia. |
B2M |
| 45 |
31423206 |
10.3892/ol.2019.10410 |
2019 |
Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma. |
B2M |
| 46 |
31597848 |
10.11406/rinketsu.60.1229 |
2019 |
[The immune microenvironment in malignant lymphoma]. |
B2M |
| 47 |
31631675 |
10.2217/bmm-2019-0303 |
2019 |
Systemic immune-inflammation index predicting survival outcome in patients with classical Hodgkin lymphoma. |
B2M |
| 48 |
31697821 |
10.1182/blood.2019002067 |
2019 |
Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. |
B2M |
| 49 |
31816062 |
10.1182/bloodadvances.2019001012 |
2019 |
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. |
B2M |
| 50 |
29289361 |
10.1016/j.blre.2017.12.001 |
2018 |
The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies. |
B2M |
| 51 |
29394125 |
10.1200/JCO.2017.77.3994 |
2018 |
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. |
B2M |
| 52 |
29625928 |
10.1016/j.clml.2018.03.005 |
2018 |
Serum Free Light Chain Difference and β<sub>2</sub> Microglobulin Levels Are Risk Factors for Thromboembolic Events in Patients With AL Amyloidosis. |
B2M |
| 53 |
29657120 |
10.1016/j.canrad.2017.11.005 |
2018 |
Breast lymphoma occurring after an invasive ductal breast carcinoma developed in the same area: A case report and literature review. |
B2M |
| 54 |
29857068 |
10.1016/j.jid.2018.04.038 |
2018 |
Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. |
B2M |
| 55 |
29872358 |
10.1177/1179299X18776974 |
2018 |
Clean Colorectum at Diagnostic Colonoscopy: Subsequent Detection of Extracolonic Malignancies by Plasma Protein Biomarkers? |
B2M |
| 56 |
30087457 |
10.1038/s41374-018-0096-6 |
2018 |
Novel cell enrichment technique for robust genetic analysis of archival classical Hodgkin lymphoma tissues. |
B2M |
| 57 |
28302137 |
10.1186/s13045-017-0438-7 |
2017 |
Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort. |
B2M |
| 58 |
28372509 |
10.1080/10428194.2017.1307981 |
2017 |
FcγRIIb expression in early stage chronic lymphocytic leukemia. |
B2M |
| 59 |
28398499 |
10.1093/annonc/mdx128 |
2017 |
Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. |
B2M |
| 60 |
28419429 |
10.1111/bjh.14633 |
2017 |
Mutational landscape of B-cell post-transplant lymphoproliferative disorders. |
B2M |
| 61 |
28807016 |
10.1186/s12885-017-3536-6 |
2017 |
Endogenous controls of gene expression in N-methyl-N-nitrosourea-induced T-cell lymphoma in p53-deficient mice. |
B2M |
| 62 |
29228708 |
10.18632/oncotarget.21963 |
2017 |
Blood biomarkers in adults with lymph node enlargement contribute to diagnostic significance of malignancy. |
B2M |
| 63 |
25689467 |
10.1002/hon.2188 |
2016 |
Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma. |
B2M |
| 64 |
26268515 |
10.1179/1607845415Y.0000000042 |
2016 |
Evaluation of serum and urine fetuin-A levels in children with acute lymphoblastic leukemia during and after high-dose methotrexate therapy: Relation to toxicity. |
B2M |
| 65 |
26732125 |
10.3109/10428194.2015.1137291 |
2016 |
Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survival. |
B2M |
| 66 |
26752561 |
10.1371/journal.pone.0146624 |
2016 |
Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas. |
B2M |
| 67 |
27110054 |
10.1155/2016/1523959 |
2016 |
The Prognostic Significance of Beta2 Microglobulin in Patients with Hemophagocytic Lymphohistiocytosis. |
B2M |
| 68 |
27276707 |
10.18632/oncotarget.9793 |
2016 |
Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. |
B2M |
| 69 |
27389058 |
10.1038/leu.2016.161 |
2016 |
Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. |
B2M |
| 70 |
27835906 |
10.18632/oncotarget.13239 |
2016 |
Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma. |
B2M |
| 71 |
27959929 |
10.1371/journal.pmed.1002197 |
2016 |
Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. |
B2M |
| 72 |
24913511 |
10.3109/10428194.2014.917640 |
2015 |
Prognostic impact of β₂-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma. |
B2M |
| 73 |
25488972 |
10.1182/blood-2014-11-610436 |
2015 |
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. |
B2M |
| 74 |
25577449 |
10.1016/j.transci.2014.12.007 |
2015 |
Beta-2 microglobulin predicts the outcome after autologous stem cell transplantation in non-Hodgkin lymphoma. |
B2M |
| 75 |
25622250 |
10.3390/ijms16022307 |
2015 |
Gentamicin arrests cancer cell growth: the intriguing involvement of nuclear sphingomyelin metabolism. |
B2M |
| 76 |
25981322 |
10.1016/j.bulcan.2015.03.013 |
2015 |
[Endocrine sequelae after treatment of pediatric cancer: From childhood to adulthood]. |
B2M |
| 77 |
25991819 |
10.1158/1078-0432.CCR-14-2116 |
2015 |
Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. |
B2M |
| 78 |
26068922 |
10.1371/journal.pone.0129298 |
2015 |
Plasma Hsp90 Level as a Marker of Early Acute Lymphoblastic Leukemia Engraftment and Progression in Mice. |
B2M |
| 79 |
26291013 |
10.1097/JTO.0000000000000624 |
2015 |
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer. |
B2M |
| 80 |
26350140 |
10.1016/j.leukres.2015.08.016 |
2015 |
Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy. |
B2M |
| 81 |
24180329 |
10.3109/10428194.2013.850167 |
2014 |
Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era. |
B2M |
| 82 |
24413734 |
10.1038/ng.2873 |
2014 |
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. |
B2M |
| 83 |
24441948 |
10.1007/s00277-014-2015-2 |
2014 |
Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma. |
B2M |
| 84 |
24454777 |
10.1371/journal.pone.0084999 |
2014 |
Correlations between functional imaging markers derived from PET/CT and diffusion-weighted MRI in diffuse large B-cell lymphoma and follicular lymphoma. |
B2M |
| 85 |
24885312 |
10.1186/1471-2164-15-390 |
2014 |
In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL). |
B2M |
| 86 |
24969158 |
10.1159/000362670 |
2014 |
Prognostic significance of serum beta-2 microglobulin in patients with non-Hodgkin lymphoma. |
B2M |
| 87 |
25171927 |
10.1182/blood-2013-12-546309 |
2014 |
Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. |
B2M |
| 88 |
25292288 |
10.1186/1471-2407-14-750 |
2014 |
Characterization of β2-microglobulin expression in different types of breast cancer. |
B2M |
| 89 |
23331211 |
10.1111/ejh.12075 |
2013 |
Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era. |
B2M |
| 90 |
23717383 |
10.1371/journal.pone.0059868 |
2013 |
Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort. |
B2M |
| 91 |
23859015 |
10.1139/bcb-2012-0110 |
2013 |
Low expression of dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin-related protein in non-Hodgkin lymphoma and significant correlations with lactic acid dehydrogenase and β2-microglobulin. |
B2M |
| 92 |
23898101 |
|
2013 |
Beta-2 microglobulin as a diagnostic parameter in non-Hodgkin lymphoma: a comparative study with FDG-PET. |
B2M |
| 93 |
22373550 |
10.1007/s00277-012-1434-1 |
2012 |
Serum beta2-microglobin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma. |
B2M |
| 94 |
22475215 |
10.3109/10428194.2012.666662 |
2012 |
Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia. |
B2M |
| 95 |
22585868 |
10.1158/2159-8290.CD-RW2011-64 |
2012 |
Gene inactivation promotes immune escape in DLBCL. |
B2M |
| 96 |
23033288 |
|
2012 |
Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma. |
B2M |
| 97 |
23226803 |
10.3892/ol.2012.913 |
2012 |
Detection of the Epstein-Barr virus in blood and bone marrow mononuclear cells of patients with aggressive B-cell non-Hodgkin's lymphoma is not associated with prognosis. |
B2M |
| 98 |
20828817 |
10.1016/j.leukres.2010.08.006 |
2011 |
Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphoma. |
B2M |
| 99 |
22137796 |
10.1016/j.ccr.2011.11.006 |
2011 |
Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. |
B2M |
| 100 |
20437868 |
|
2010 |
Prognostic factors in follicular lymphoma: the importance of beta-2 microglobulin. |
B2M |
Datasets
Models
